SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya

[1]  M. Masika,et al.  High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya , 2021, International Journal of Infectious Diseases.

[2]  J. Scott,et al.  Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya , 2021, Nature Communications.

[3]  M. Keeling,et al.  COVID-19 transmission dynamics underlying epidemic waves in Kenya , 2021, Science.

[4]  M. Keeling,et al.  Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data , 2021, Wellcome open research.

[5]  M. Kåberg,et al.  Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic , 2021, Harm Reduction Journal.

[6]  A. Kurniawan,et al.  Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis , 2021, Southern African journal of HIV medicine.

[7]  B. Chohan,et al.  Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol , 2021, BMJ Open.

[8]  N. Jones,et al.  Risk of adverse coronavirus disease 2019 outcomes for people living with HIV , 2021, AIDS (London, England).

[9]  J. Scott,et al.  Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals , 2021, medRxiv.

[10]  David R. Holtgrave,et al.  COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State , 2021, JAMA network open.

[11]  Nanor Minoyan,et al.  A rapid review of the impacts of “Big Events ” on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19 , 2021, International journal of drug policy.

[12]  J. Scott,et al.  Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.

[13]  D. Cattaneo,et al.  Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV , 2020, HIV medicine.

[14]  M. Davies,et al.  COVID-19 in-hospital mortality in South Africa: the intersection of communicable and non-communicable chronic diseases in a high HIV prevalence setting , 2020, medRxiv.

[15]  G. Mohler,et al.  Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis , 2020, Journal of Urban Health.

[16]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[17]  P. Sax,et al.  Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  B. Marshall,et al.  Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19 , 2020, International Journal of Drug Policy.

[19]  Marie Tré-Hardy,et al.  Analytical and clinical validation of an ELISA for specific SARS‐CoV‐2 IgG, IgA, and IgM antibodies , 2020, Journal of medical virology.

[20]  Jessica K De Freitas,et al.  Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients in New York City. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. López-Vélez,et al.  Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.

[22]  P. Dietze,et al.  Illicit drug use and harms in Australia in the context of COVID‐19 and associated restrictions: Anticipated consequences and initial responses , 2020, Drug and alcohol review.

[23]  M. Giles,et al.  Results from a mobile outreach influenza vaccination program for vulnerable and high‐risk populations in a high‐income setting: lessons learned , 2018, Australian and New Zealand journal of public health.

[24]  E. Akl,et al.  WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. , 2014, The International journal on drug policy.

[25]  R. D. Bruce,et al.  Adherence to hepatitis B virus vaccination at syringe exchange sites , 2005, Journal of Urban Health.

[26]  S. Friedman,et al.  "Big Events" and Networks. , 2006, Connections.

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..